► Home ﹥News

  ActivitiesPharmaEssentia not only has an outstanding performance in Taiwan R&D field but also actively participates numerous international Bio conferences and presentations. The following are the conferences and activities we participate from 2007 to present… read more

  11 December, 2009(Taiwan) PharmaEssentia announces commencement of Phase I clinical trial for its HBV/HCV drug candidate P1101 (PEG-P-IFN-alpha)… read more

  28 November, 2009Dr. ChingLeou Teng was appointed as the Chairman and Dr. KOChung Lin was appointed as CEO of PharmaEssentia by the BOD on Nov 28th, 2009.

  12 August, 2009PharmaEssentia Receives FDA Approval for Hepatitis Drug… read more

  4 August, 2009PharmaEssentia's long-acting HC/BV drug candidate P1101 (PEG-P-IFN-alpha-2b) receives FDA IND approval… read more

  14 February, 2009(Taiwan) PharmaEssentia and ScinoPharm sign supply agreement, announce progress on next-generation EPO… read more

  18 June, 2008PharmaEssentia announces milestone in development of new third-generation interferon hepatitis B and C drug candidate… read more

  15 May, 2008Mixing protein engineering, chemistry for new drugs… read more

  14 February, 2008PharmaEssentia signs CoQ10 manufacturing licensing deal with Malaysia's Black Gold Global… read more

  4 July, 2007PharmaEssentia ramps up int'l networking, announces schedule for new HBV/HCV drug candidate… read more

  5 April, 2007Article in Nature Magazine's 5 April 2008 'Spotlight on Taiwan' special issue… read more

  7 August, 2006PharmaEssentia unveils PharmaQ10 branded CoQ10… read more


Copyright © 2008 PharmaEssentia Corporation All Rights Reserved.